• Elizabeth E. Reed, chief legal officer and general counsel at Travere Therapeutics, reported sales tied to equity transactions, ending with 105,211 shares of common stock owned directly.
• Disclosure shows exercise of 20,000 stock options at USD 17.96 on May 4, 2026, followed by sale of 20,000 shares at USD 45 the same day.
• Filing also reflects vesting of performance-based restricted stock units, with subsequent sales of 2,174 shares at USD 46.65 on May 5, 2026, then 2,076 shares at USD 43.95 on May 6, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001283303-26-000009), on May 06, 2026, and is solely responsible for the information contained therein.